Menu
Recruiting NCT06650813

Adapting the FACETS Program to Sickle Cell Disease

No phase Interventional Fatigue Symptom Sickle Cell Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Drépa-FACETS Program.
Who it may be relevant to
Registry conditions: Fatigue Symptom, Sickle Cell Disease. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Adapting the FACETS Fatigue Management Program to Sickle Cell Disease

Overview

Adaptation of a fatigue management program combining the principles of cognitive-behavioral therapy and energy conservation strategies (FACETS program) for a population of adult patients with sickle cell disease (Drépa-FACETS program).

Interventions

  • Other Drépa-FACETS Program
    Drépa-FACETS Program for Sickle Cell Disease

Primary outcome measures

  • Feasibility of the FACETS program for adult sickle-cell patients [Time frame: From the enrollment to the end of the protocol visits (10 weeks)]

Eligibility criteria

Inclusion criteria

  • Participant having freely given his oral agreement.
  • Participant with a major sickle cell syndrome, regardless of genotype (e.g. SS, SC, Sbeta).
  • Participant with a sufficient command of spoken and written French to take the assessments, complete the questionnaires, follow the program sessions and carry out the home exercises.

Exclusion criteria

  • Participant with one or more severe psychiatric pathologies (e.g. severe depression, psychosis) that could interfere with the conduct of the study, in particular the primary and secondary endpoints.
  • Participants with another chronic pathology causing fatigue.
  • Participants in vaso-occlusive crisis (VOC) or hospitalization.
  • Participant under legal protection (guardianship, curatorship, safeguard of justice, deprived of liberty).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Prevention

Study locations

France · 2 centers
  • CHU Grenoble Alpes — Grenoble
  • Hospital Versailles — Le Chesnay

Identifiers

NCT: NCT06650813 · P23/09 - Drépa-FACETS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗